Diann Blanset - Concepedia

Author

Diann Blanset

Boehringer Ingelheim (United States)

Also Known As

D Blanset, D. Blanset, Diann Blanset, Diann L. Blanset

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (United States)Pfizer (United States)Bristol-Myers Squibb (United States)Eli Lilly (United States)United States Military Academy

About

Diann Blanset is an author at Boehringer Ingelheim (United States) specializing in medicine, immunotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	813
2	Allergy	3	3	208
3	Public Health	2	2	61
4	Engineering	1	1	13
5	Management	1	1	41

Diann Blanset

Publications

Citations

H-Index

Page 1

	Year	Citations
<i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates Changyu Wang, Kent Thudium, Minhua Han, Cancer Immunology Research	2014	585
Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma Stephen M. Ansell, Steven M. Horwitz, Andreas Engert, Journal of Clinical Oncology	2007	251
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo Susanne Hipp, YT Tai, Diann Blanset, Leukemia Hematological MalignancyCancer ImmunosurveillanceMalignant Blood DisorderImmunologyBone Marrow	2016	228
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology Mark Selby, John Engelhardt, Robert J. Johnston, PLoS ONE ImmunologyPathologyImmunotherapeuticsImmunotherapyTumor Biology	2016	225
CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques Anna Hryniewicz, Adriano Boasso, Yvette Edghill‐Smith, Blood	2006	165
Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques Tibor Keler, Ed Halk, Laura Vitale, The Journal of Immunology	2003	132
Use of Tissue Cross-reactivity Studies in the Development of Antibody-based Biopharmaceuticals Michael W. Leach, Wendy Halpern, Carol W. Johnson, Toxicologic Pathology Tissue Cross-reactivityImmunocytochemical TechniqueImmunologyTissue Cross-reactivity StudiesPathology	2010	98
Prophylaxis and Therapy of Inhalational Anthrax by a Novel Monoclonal Antibody to Protective Antigen That Mimics Vaccine-Induced Immunity Laura Vitale, Diann Blanset, Israel Lowy, Infection and Immunity ImmunologyImmunodominanceMimics Vaccine-induced ImmunityImmunotherapeuticsInhalational Anthrax	2006	90
A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies Pina M. Cardarelli, Chetana Rao‐Naik, Sharline Chen, Cancer Immunology Immunotherapy B-cell MalignanciesMalignant Blood DisorderImmunologyImmune Checkpoint InhibitorAutoimmunity	2009	47
Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology Stanley Roberts, Paul A. Andrews, Diann Blanset, Regulatory Toxicology and Pharmacology OncologyPolymer-drug ConjugatePharmacologyAntibody EngineeringAnti-cancer Agent	2013	43

Page 1